Healthy Q1 prompts guidance upgrade
13/05/22 -"Genmab reported a healthy set of Q1 results. This impressive performance was witnessed across the offerings, which were again led by Darzalex. Despite maintaining aggressive spending plans, the 2022 ..."
Pages
48
Language
English
Published on
13/05/22
You may also be interested by these reports :
17/09/25
The massive collapse in Novo Nordisk’s share price over the last 15 months, due to competitive concerns, pricing pressure and a few other factors, ...
25/08/25
Attractive return potential remains – Confidence slightly raised
22/08/25
Though missing expectations, Novonesis demonstrated strong momentum in H1 2025, achieving 9% organic growth and 8% in Q2, resulting in a narrowed ...
21/08/25
Guidance reaffirmed while FX and destocking mask momentum